Literature DB >> 32816858

A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.

Michal Shreberk-Shaked1, Bareket Dassa2, Sanju Sinha3,4, Silvia Di Agostino5, Ido Azuri2, Saptaparna Mukherjee1, Yael Aylon1, Giovanni Blandino5, Eytan Ruppin3,4, Moshe Oren6.   

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. The paralogous transcriptional cofactors Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ, also called WWTR1), the main downstream effectors of the Hippo signal transduction pathway, are emerging as pivotal determinants of malignancy in lung cancer. Traditionally, studies have tended to consider YAP and TAZ as functionally redundant transcriptional cofactors with similar biological impact. However, there is growing evidence that each of them also possesses distinct attributes. Here we sought to systematically characterize the division of labor between YAP and TAZ in non-small cell lung cancer (NSCLC), the most common histological subtype of lung cancer. Representative NSCLC cell lines as well as patient-derived data showed that the two paralogs orchestrated nonoverlapping transcriptional programs in this cancer type. YAP preferentially regulated gene sets associated with cell division and cell-cycle progression, whereas TAZ preferentially regulated genes associated with extracellular matrix organization. Depletion of YAP resulted in growth arrest, whereas its overexpression promoted cell proliferation. Likewise, depletion of TAZ compromised cell migration, whereas its overexpression enhanced migration. The differential effects of YAP and TAZ on key cellular processes were also associated with differential response to anticancer therapies. Uncovering the different activities and downstream effects of YAP and TAZ may thus facilitate better stratification of patients with lung cancer for anticancer therapies. SIGNIFICANCE: Thease findings show that oncogenic paralogs YAP and TAZ have distinct roles in NSCLC and are associated with differential response to anticancer drugs, knowledge that may assist lung cancer therapy decisions. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32816858      PMCID: PMC8916161          DOI: 10.1158/0008-5472.CAN-20-0125

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states.

Authors:  Ronnie Blecher-Gonen; Zohar Barnett-Itzhaki; Diego Jaitin; Daniela Amann-Zalcenstein; David Lara-Astiaso; Ido Amit
Journal:  Nat Protoc       Date:  2013-02-21       Impact factor: 13.491

2.  YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression.

Authors:  Yijun Gao; Wenjing Zhang; Xiangkun Han; Fuming Li; Xujun Wang; Rui Wang; Zhaoyuan Fang; Xinyuan Tong; Shun Yao; Fei Li; Yan Feng; Yihua Sun; Yingyong Hou; Zhongzhou Yang; Kunliang Guan; Haiquan Chen; Lei Zhang; Hongbin Ji
Journal:  Nat Commun       Date:  2014-08-13       Impact factor: 14.919

3.  The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells.

Authors:  Giulia Gobbi; Benedetta Donati; Italo Faria Do Valle; Francesca Reggiani; Federica Torricelli; Daniel Remondini; Gastone Castellani; Davide Carlo Ambrosetti; Alessia Ciarrocchi; Valentina Sancisi
Journal:  Oncogene       Date:  2019-08-12       Impact factor: 9.867

4.  Next-generation characterization of the Cancer Cell Line Encyclopedia.

Authors:  Mahmoud Ghandi; Franklin W Huang; Judit Jané-Valbuena; Gregory V Kryukov; Christopher C Lo; E Robert McDonald; Jordi Barretina; Ellen T Gelfand; Craig M Bielski; Haoxin Li; Kevin Hu; Alexander Y Andreev-Drakhlin; Jaegil Kim; Julian M Hess; Brian J Haas; François Aguet; Barbara A Weir; Michael V Rothberg; Brenton R Paolella; Michael S Lawrence; Rehan Akbani; Yiling Lu; Hong L Tiv; Prafulla C Gokhale; Antoine de Weck; Ali Amin Mansour; Coyin Oh; Juliann Shih; Kevin Hadi; Yanay Rosen; Jonathan Bistline; Kavitha Venkatesan; Anupama Reddy; Dmitriy Sonkin; Manway Liu; Joseph Lehar; Joshua M Korn; Dale A Porter; Michael D Jones; Javad Golji; Giordano Caponigro; Jordan E Taylor; Caitlin M Dunning; Amanda L Creech; Allison C Warren; James M McFarland; Mahdi Zamanighomi; Audrey Kauffmann; Nicolas Stransky; Marcin Imielinski; Yosef E Maruvka; Andrew D Cherniack; Aviad Tsherniak; Francisca Vazquez; Jacob D Jaffe; Andrew A Lane; David M Weinstock; Cory M Johannessen; Michael P Morrissey; Frank Stegmeier; Robert Schlegel; William C Hahn; Gad Getz; Gordon B Mills; Jesse S Boehm; Todd R Golub; Levi A Garraway; William R Sellers
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

5.  Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration.

Authors:  James L Grijalva; Megan Huizenga; Kaly Mueller; Steven Rodriguez; Joseph Brazzo; Fernando Camargo; Ghazaleh Sadri-Vakili; Khashayar Vakili
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-29       Impact factor: 4.052

6.  The Hippo pathway controls border cell migration through distinct mechanisms in outer border cells and polar cells of the Drosophila ovary.

Authors:  Tzu-Huai Lin; Tsung-Han Yeh; Tsu-Wei Wang; Jenn-Yah Yu
Journal:  Genetics       Date:  2014-08-26       Impact factor: 4.562

7.  Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features.

Authors:  Sharathchandra Arandkar; Noa Furth; Yair Elisha; Nishanth Belugali Nataraj; Heiko van der Kuip; Yosef Yarden; Walter Aulitzky; Igor Ulitsky; Benjamin Geiger; Moshe Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-04       Impact factor: 11.205

8.  DrugBank 5.0: a major update to the DrugBank database for 2018.

Authors:  David S Wishart; Yannick D Feunang; An C Guo; Elvis J Lo; Ana Marcu; Jason R Grant; Tanvir Sajed; Daniel Johnson; Carin Li; Zinat Sayeeda; Nazanin Assempour; Ithayavani Iynkkaran; Yifeng Liu; Adam Maciejewski; Nicola Gale; Alex Wilson; Lucy Chin; Ryan Cummings; Diana Le; Allison Pon; Craig Knox; Michael Wilson
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

Review 9.  YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting.

Authors:  Federica Lo Sardo; Sabrina Strano; Giovanni Blandino
Journal:  Cancers (Basel)       Date:  2018-05-06       Impact factor: 6.639

10.  Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development.

Authors:  Antoine Reginensi; Rizaldy P Scott; Alex Gregorieff; Mazdak Bagherie-Lachidan; Chaeuk Chung; Dae-Sik Lim; Tony Pawson; Jeff Wrana; Helen McNeill
Journal:  PLoS Genet       Date:  2013-03-21       Impact factor: 5.917

View more
  10 in total

1.  TAZ is important for maintenance of the integrity of podocytes.

Authors:  Jianchun Chen; Xiaoyong Wang; Qian He; Raymond C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2022-02-14

2.  Combined control of the fibroblast contractile program by YAP and TAZ.

Authors:  Patrick A Link; Kyoung Moo Choi; Ana M Diaz Espinosa; Dakota L Jones; Ashley Y Gao; Andrew J Haak; Daniel J Tschumperlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-11-10       Impact factor: 5.464

3.  A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma.

Authors:  Chunle Zhao; Jun Gong; Yu Bai; Taoyuan Yin; Min Zhou; Shutao Pan; Yuhui Liu; Yang Gao; Zhenxiong Zhang; Yongkang Shi; Feng Zhu; Hang Zhang; Min Wang; Renyi Qin
Journal:  Cell Death Differ       Date:  2022-07-29       Impact factor: 12.067

4.  Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins.

Authors:  Saptaparna Mukherjee; Martino Maddalena; YiQing Lü; Sebastien Martinez; Nishanth Belugali Nataraj; Ashish Noronha; Sansrity Sinha; Katie Teng; Victoria Cohen-Kaplan; Tamar Ziv; Sharathchandra Arandkar; Ori Hassin; Rishita Chatterjee; Anna-Chiara Pirona; Michal Shreberk-Shaked; Anat Gershoni; Yael Aylon; Zvulun Elazar; Yosef Yarden; Daniel Schramek; Moshe Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-19       Impact factor: 12.779

Review 5.  Context-dependent roles of YAP/TAZ in stem cell fates and cancer.

Authors:  Lucy LeBlanc; Nereida Ramirez; Jonghwan Kim
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

Review 6.  YAP and endothelin-1 signaling: an emerging alliance in cancer.

Authors:  Piera Tocci; Giovanni Blandino; Anna Bagnato
Journal:  J Exp Clin Cancer Res       Date:  2021-01-09

Review 7.  The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.

Authors:  Ángel Ortega; Ivana Vera; Maria P Diaz; Carla Navarro; Milagros Rojas; Wheeler Torres; Heliana Parra; Juan Salazar; Juan B De Sanctis; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

8.  YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.

Authors:  Lizhi He; Henry Pratt; Mingshi Gao; Fengxiang Wei; Zhiping Weng; Kevin Struhl
Journal:  Elife       Date:  2021-08-31       Impact factor: 8.140

Review 9.  The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer.

Authors:  Yu Jiang; Wen-Jing Xie; Rong-Wei Chen; Wei-Wei You; Wei-Lin Ye; Hong Chen; Wen-Xu Chen; Jian-Ping Xu
Journal:  Front Surg       Date:  2022-03-21

10.  Desmoglein-3 induces YAP phosphorylation and inactivation during collective migration of oral carcinoma cells.

Authors:  Usama Sharif Ahmad; Eric Kenneth Parkinson; Hong Wan
Journal:  Mol Oncol       Date:  2022-03-01       Impact factor: 7.449

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.